Summary

The 7 major hypertrophic cardiomyopathy markets reached a value of US$ 312.5 Million in 2023. Looking forward, IMARC Group expects the 7MM to reach US$ 356.7 Million by 2034, exhibiting a growth rate (CAGR) of 1.21% during 2024-2034.

The hypertrophic cardiomyopathy market has been comprehensively analyzed in IMARC's new report titled "Hypertrophic Cardiomyopathy Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Hypertrophic cardiomyopathy refers to a condition in which the cardiac muscle becomes abnormally thick. The parts of the heart most frequently affected are the ventricles and the interventricular septum. This can make the heart walls stiff and reduce its ability to pump blood effectively, resulting in electrical conduction problems. Individuals suffering from the disease may experience fatigue, leg swelling, shortness of breath, chest pain, fainting, etc. The other common symptoms of hypertrophic cardiomyopathy include abnormal heart rhythms (arrhythmias), dizziness, lightheadedness, etc. These indications may be worse if a person is dehydrated. The diagnosis of the ailment is typically made using the medical history and underlying symptoms of the patient, along with a physical exam and laboratory tests. The healthcare provider may also perform numerous diagnostic procedures, such as an electrocardiogram, cardiac magnetic resonance imaging, echocardiogram, etc. Additionally, stress tests and genetic testing can be utilized to confirm a diagnosis among patients.

The rising cases of inherited genetic mutations that affect the proteins in heart muscle cells are primarily driving the hypertrophic cardiomyopathy market. In addition to this, the elevating incidences of several associated risk factors, including sedentary lifestyle, obesity, aging, high blood pressure, intense endurance exercise, etc., are further augmenting the market growth. Moreover, the emerging popularity of effective medications, such as beta-blockers, calcium channel blockers, diuretics, etc., for reducing the heart's workload and improving blood flow among patients is also creating a positive outlook for the market. Apart from this, the widespread adoption of transesophageal echocardiogram (TEE), which utilizes sound waves to create a superior quality image of the heart structures with greater depth and provide confirmed disease diagnosis, is further bolstering the market growth. Additionally, the escalating utilization of alcohol septal ablation, a non-surgical procedure, to treat the condition by injecting alcohol into one or more septal branches of the left anterior descending artery, is acting as another significant growth-inducing factor. Besides this, the rising usage of implantable cardioverter defibrillator therapy that can prevent sudden death in patients with an increased risk of ventricular arrhythmias, is expected to drive the hypertrophic cardiomyopathy market in the comipng years.

IMARC Group's new report provides an exhaustive analysis of the hypertrophic cardiomyopathy market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for hypertrophic cardiomyopathy and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the hypertrophic cardiomyopathy market in any manner.

Time Period of the Study

Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034

Countries Covered

United States
Germany
France
United Kingdom
Italy
Spain
Japan

Analysis Covered Across Each Country

Historical, current, and future epidemiology scenario
Historical, current, and future performance of the hypertrophic cardiomyopathy market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the hypertrophic cardiomyopathy market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current hypertrophic cardiomyopathy marketed drugs and late-stage pipeline drugs.

In-Market Drugs

Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance

Late-Stage Pipeline Drugs

Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance

Drugs Company Name
Camzyos (Mavacamten) Britol Myers Squibb/MyoKardia
CK 3773274 Cytokinetics
IMB-1018972 Imbria Pharmaceuticals
LCZ696 Novartis

*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report:
Market Insights

How has the hypertrophic cardiomyopathy market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the hypertrophic cardiomyopathy market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the hypertrophic cardiomyopathy market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?

Epidemiology Insights

What is the number of prevalent cases (​2018-2034​) of hypertrophic cardiomyopathy across the seven major markets?
What is the number of prevalent cases (​2018-2034​) of hypertrophic cardiomyopathy by age across the seven major markets?
What is the number of prevalent cases (​2018-2034​) of hypertrophic cardiomyopathy by gender across the seven major markets?
How many patients are diagnosed (​2018-2034​) with hypertrophic cardiomyopathy across the seven major markets?
What is the size of the hypertrophic cardiomyopathy patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of hypertrophic cardiomyopathy?
What will be the growth rate of patients across the seven major markets?

Hypertrophic Cardiomyopathy: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for hypertrophic cardiomyopathy drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the hypertrophic cardiomyopathy market?
What are the key regulatory events related to the hypertrophic cardiomyopathy market?
What is the structure of clinical trial landscape by status related to the hypertrophic cardiomyopathy market?
What is the structure of clinical trial landscape by phase related to the hypertrophic cardiomyopathy market?
What is the structure of clinical trial landscape by route of administration related to the hypertrophic cardiomyopathy market?

ページTOPに戻る

Table of Contents

1 Preface

2 Scope and Methodology
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology

3 Executive Summary

4 Hypertrophic Cardiomyopathy - Introduction
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence

5 Hypertrophic Cardiomyopathy - Disease Overview
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment

6 Patient Journey

7 Hypertrophic Cardiomyopathy - Epidemiology and Patient Population
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (​2018-2034​)
7.2.4 Epidemiology by Gender (​2018-2034​)
7.2.5 Diagnosed Cases (​2018-2034​)
7.2.6 Patient Pool/Treated Cases (​2018-2034​)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (​2018-2034​)
7.3.4 Epidemiology by Gender (​2018-2034​)
7.3.5 Diagnosed Cases (​2018-2034​)
7.3.6 Patient Pool/Treated Cases (​2018-2034​)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (​2018-2034​)
7.4.4 Epidemiology by Gender (​2018-2034​)
7.4.5 Diagnosed Cases (​2018-2034​)
7.4.6 Patient Pool/Treated Cases (​2018-2034​)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (​2018-2034​)
7.5.4 Epidemiology by Gender (​2018-2034​)
7.5.5 Diagnosed Cases (​2018-2034​)
7.5.6 Patient Pool/Treated Cases (​2018-2034​)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (​2018-2034​)
7.6.4 Epidemiology by Gender (​2018-2034​)
7.6.5 Diagnosed Cases (​2018-2034​)
7.6.6 Patient Pool/Treated Cases (​2018-2034​)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (​2018-2034​)
7.7.4 Epidemiology by Gender (​2018-2034​)
7.7.5 Diagnosed Cases (​2018-2034​)
7.7.6 Patient Pool/Treated Cases (​2018-2034​)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (​2018-2034​)
7.8.4 Epidemiology by Gender (​2018-2034​)
7.8.5 Diagnosed Cases (​2018-2034​)
7.8.6 Patient Pool/Treated Cases (​2018-2034​)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (​2018-2034​)
7.9.4 Epidemiology by Gender (​2018-2034​)
7.9.5 Diagnosed Cases (​2018-2034​)
7.9.6 Patient Pool/Treated Cases (​2018-2034​)

8 Hypertrophic Cardiomyopathy - Treatment Algorithm, Guidelines, and Medical Practices
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm

9 Hypertrophic Cardiomyopathy - Unmet Needs

10 Hypertrophic Cardiomyopathy - Key Endpoints of Treatment

11 Hypertrophic Cardiomyopathy - Marketed Products
11.1 List of Hypertrophic Cardiomyopathy Marketed Drugs Across the Top 7 Markets
11.1.1 Camzyos (Mavacamten) - Britol Myers Squibb/MyoKardia
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets

Kindly note that the above only represents a partial list of marketed drugs, and the complete list has been provided in the report.

12 Hypertrophic Cardiomyopathy - Pipeline Drugs
12.1 List of Hypertrophic Cardiomyopathy Pipeline Drugs Across the Top 7 Markets
12.1.1 CK 3773274 - Cytokinetics
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
12.1.2 IMB-1018972 - Imbria Pharmaceuticals
12.1.2.1 Drug Overview
12.1.2.2 Mechanism of Action
12.1.2.3 Clinical Trial Results
12.1.2.4 Safety and Efficacy
12.1.2.5 Regulatory Status
12.1.3 LCZ696 - Novartis
12.1.3.1 Drug Overview
12.1.3.2 Mechanism of Action
12.1.3.3 Clinical Trial Results
12.1.3.4 Safety and Efficacy
12.1.3.5 Regulatory Status

Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.

13. Hypertrophic Cardiomyopathy - Attribute Analysis of Key Marketed and Pipeline Drugs

14. Hypertrophic Cardiomyopathy – Clinical Trial Landscape
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events

15 Hypertrophic Cardiomyopathy - Market Scenario
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Hypertrophic Cardiomyopathy - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Hypertrophic Cardiomyopathy - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Hypertrophic Cardiomyopathy - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Hypertrophic Cardiomyopathy - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Hypertrophic Cardiomyopathy - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Hypertrophic Cardiomyopathy - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Hypertrophic Cardiomyopathy - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Hypertrophic Cardiomyopathy - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Hypertrophic Cardiomyopathy - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Hypertrophic Cardiomyopathy - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Hypertrophic Cardiomyopathy - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Hypertrophic Cardiomyopathy - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Hypertrophic Cardiomyopathy - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Hypertrophic Cardiomyopathy - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Hypertrophic Cardiomyopathy - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Hypertrophic Cardiomyopathy - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Hypertrophic Cardiomyopathy - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Hypertrophic Cardiomyopathy - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Hypertrophic Cardiomyopathy - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Hypertrophic Cardiomyopathy - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Hypertrophic Cardiomyopathy - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Hypertrophic Cardiomyopathy - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Hypertrophic Cardiomyopathy - Access and Reimbursement Overview

16 Hypertrophic Cardiomyopathy - Recent Events and Inputs From Key Opinion Leaders

17 Hypertrophic Cardiomyopathy Market - SWOT Analysis
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats

18 Hypertrophic Cardiomyopathy Market – Strategic Recommendations

19 Appendix